Literature DB >> 17881812

Peripheral dose in ocular treatments with CyberKnife and Gamma Knife radiosurgery compared to proton radiotherapy.

A Zytkovicz1, I Daftari, T L Phillips, C F Chuang, L Verhey, P L Petti.   

Abstract

Peripheral radiation can have deleterious effects on normal tissues throughout the body, including secondary cancer induction and cataractogenesis. The aim of this study is to evaluate the peripheral dose received by various regions of the body after ocular treatment delivered with the Model C Gamma Knife, proton radiotherapy with a dedicated ocular beam employing no passive-scattering system, or a CyberKnife unit before and after supplemental shielding was introduced. TLDs were used for stray gamma and x-ray dosimetry, whereas CR-39 dosimeters were used to measure neutron contamination in the proton experiments. Doses to the contralateral eye, neck, thorax and abdomen were measured on our anthropomorphic phantom for a 56 Gy treatment to a 588 mm(3) posterior ocular lesion. Gamma Knife (without collimator blocking) delivered the highest dose in the contralateral eye, with 402-2380 mSv, as compared with 118-234 mSv for CyberKnife pre-shielding, 46-255 mSv for CyberKnife post-shielding and 9-12 mSv for proton radiotherapy. Gamma Knife and post-shielding CyberKnife delivered comparable doses proximal to the treatment site, with 190 versus 196 mSv at the thyroid, whereas protons doses at these locations were less than 10 mSv. Gamma Knife doses decreased dramatically with distance from the treatment site, delivering only 13 mSv at the lower pelvis, comparable to the proton result of 4 to 7 mSv in this region. In contrast, CyberKnife delivered between 117 and 132 mSv to the lower pelvis. In conclusion, for ocular melanoma treatments, a proton beam employing no double scattering system delivers the lowest peripheral doses proximally to the contralateral eye and thyroid when compared to radiosurgery with the Model C Gamma Knife or CyberKnife. At distal locations in the pelvis, peripheral doses delivered with proton and Gamma Knife are of an order of magnitude smaller than those delivered with CyberKnife.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881812     DOI: 10.1088/0031-9155/52/19/016

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

2.  Evaluation of the peripheral dose in stereotactic radiotherapy and radiosurgery treatments.

Authors:  Erika Di Betta; Laura Fariselli; Achille Bergantin; Federica Locatelli; Antonella Del Vecchio; Sara Broggi; Maria Luisa Fumagalli
Journal:  Med Phys       Date:  2010-07       Impact factor: 4.071

3.  An analytic model of neutron ambient dose equivalent and equivalent dose for proton radiotherapy.

Authors:  Rui Zhang; Angélica Pérez-Andújar; Jonas D Fontenot; Phillip J Taddei; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

Review 4.  [CyberKnife®: new treatment option for uveal melanoma].

Authors:  J M Mor; R Semrau; W Baus; K R Koch; F Schaub; C Cursiefen; S Marnitz; L M Heindl
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

5.  Peripheral doses in patients undergoing Cyberknife treatment for intracranial lesions. A single centre experience.

Authors:  Vassiliki Vlachopoulou; Christos Antypas; Harry Delis; Argyrios Tzouras; Nikolaos Salvaras; Dimitrios Kardamakis; George Panayiotakis
Journal:  Radiat Oncol       Date:  2011-11-14       Impact factor: 3.481

Review 6.  Uveal Melanoma: Current Trends in Diagnosis and Management.

Authors:  Berçin Tarlan; Hayyam Kıratlı
Journal:  Turk J Ophthalmol       Date:  2016-06-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.